Back to School: How biopharma can reboot drug development. Access exclusive analysis here

0910 BTS46 Yancopoulos podcast
BioCentury & Getty Images

Back to School 2020

COVID-19 should spur massive investment in science and technology, Regeneron’s Yancopoulos says: a BioCentury audio interview

Investments in manufacturing and new technologies will be needed for future emergencies, including growing chronic diseases

Investments in manufacturing and new technologies will be needed for future emergencies, including growing chronic diseases, according to Regeneron’s George Yancopoulos. 

Sep 11, 2020 | 2:26 AM GMT

In addition to preparing for future pandemics, the U.S. should increase its investments in science and technology by orders of magnitude to head off crippling onslaughts of disease, Regeneron’s George Yancopoulos told BioCentury.

In a Back to School audio interview, Yancopoulos, president and CSO of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), called out the need to invest in infrastructure capabilities, and made the case for ramping up the innovation ecosystem. The interview was one in a series with key opinion leaders for the Back to School 2020 package (see Cover Story: “The Imperative of COVID-19”). 

“I do think that society has to decide what it wants to invest in,” said Yancopoulos. “I think that investing in major biomanufacturing capacity that could be used in these sorts of emergencies would be something that society should be doing.”  

While pandemic preparedness, including investing in

Read the full 2000 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE